scholarly journals Microbiota-derived metabolites inhibit Salmonella virulent subpopulation development by acting on single-cell behaviors

2021 ◽  
Author(s):  
Alyson M Hockenberry ◽  
Gabriele Micali ◽  
Gabriella Takács ◽  
Jessica Weng ◽  
Wolf-Dietrich Hardt ◽  
...  

AbstractSalmonella spp. express Salmonella pathogenicity island 1 (SPI-1) genes to mediate the initial phase of interaction with host cells. Prior studies indicate short-chain fatty acids, microbial metabolites at high concentrations in the gastrointestinal tract, limit SPI-1 gene expression. A number of reports show only a subset of Salmonella cells in a population express these genes, suggesting short-chain fatty acids could decrease SPI-1 population-level expression by acting on per-cell expression and/or the proportion of expressing cells. Here, we combine single-cell, theoretical, and molecular approaches to address the effect of short-chain fatty acids on SPI-1 expression. Our results show short-chain fatty acids do not repress SPI-1 expression by individual cells. Rather, these compounds act to selectively slow the growth of SPI-1 expressing cells, ultimately decreasing their frequency in the population. Further experiments indicate slowed growth arises from short-chain fatty acid-mediated depletion of the proton motive force. By influencing the SPI-1 cell-type proportions, our findings imply gut microbial metabolites act on cooperation between the two cell-types and ultimately influence Salmonella’s capacity to establish within a host.Significance StatementEmergence of distinct cell-types in populations of genetically identical bacteria is common. Furthermore, it is becoming increasingly clear that cooperation between cell-types can be beneficial. This is the case during Salmonella infection, in which cooperation between inflammation-inducing virulent and fast-growing avirulent cell-types occurs during infection to aid in colonization of the host gut. Here, we show gut microbiota-derived metabolites slow growth by the virulent cell-type. Our study implies microbial metabolites shape cooperative interactions between the virulent and avirulent cell types, a finding that can help explain the wide array of clinical manifestations of Salmonella infection.

2021 ◽  
Vol 118 (31) ◽  
pp. e2103027118
Author(s):  
Alyson M. Hockenberry ◽  
Gabriele Micali ◽  
Gabriella Takács ◽  
Jessica Weng ◽  
Wolf-Dietrich Hardt ◽  
...  

Salmonella spp. express Salmonella pathogenicity island 1 Type III Secretion System 1 (T3SS-1) genes to mediate the initial phase of interaction with their host. Prior studies indicate short-chain fatty acids, microbial metabolites at high concentrations in the gastrointestinal tract, limit population-level T3SS-1 gene expression. However, only a subset of Salmonella cells in a population express these genes, suggesting short-chain fatty acids could decrease T3SS-1 population-level expression by acting on per-cell expression or the proportion of expressing cells. Here, we combine single-cell, theoretical, and molecular approaches to address the effect of short-chain fatty acids on T3SS-1 expression. Our in vitro results show short-chain fatty acids do not repress T3SS-1 expression by individual cells. Rather, these compounds act to selectively slow the growth of T3SS-1–expressing cells, ultimately decreasing their frequency in the population. Further experiments indicate slowed growth arises from short-chain fatty acid–mediated depletion of the proton motive force. By influencing the T3SS-1 cell-type proportions, our findings imply gut microbial metabolites act on cooperation between the two cell types and ultimately influence Salmonella’s capacity to establish within a host.


2019 ◽  
Vol 10 (12) ◽  
pp. 7973-7982 ◽  
Author(s):  
Yi Wan ◽  
Wenfeng Tong ◽  
Renke Zhou ◽  
Jie Li ◽  
Jihong Yuan ◽  
...  

A diet with higher animal-based fat consumption is likely to be associated with moderately unfavorable impacts on gut microbial diversity, community, and regulation of fecal short-chain fatty acids.


Science ◽  
2013 ◽  
Vol 341 (6145) ◽  
pp. 569-573 ◽  
Author(s):  
P. M. Smith ◽  
M. R. Howitt ◽  
N. Panikov ◽  
M. Michaud ◽  
C. A. Gallini ◽  
...  

Nutrients ◽  
2015 ◽  
Vol 7 (4) ◽  
pp. 2839-2849 ◽  
Author(s):  
Mayu Kasubuchi ◽  
Sae Hasegawa ◽  
Takero Hiramatsu ◽  
Atsuhiko Ichimura ◽  
Ikuo Kimura

Toxins ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 175
Author(s):  
Mostafa Asadpoor ◽  
Georgia-Nefeli Ithakisiou ◽  
Paul A. J. Henricks ◽  
Roland Pieters ◽  
Gert Folkerts ◽  
...  

Enterotoxin-producing bacteria (EPB) have developed multiple mechanisms to disrupt gut homeostasis, and provoke various pathologies. A major part of bacterial cytotoxicity is attributed to the secretion of virulence factors, including enterotoxins. Depending on their structure and mode of action, enterotoxins intrude the intestinal epithelium causing long-term consequences such as hemorrhagic colitis. Multiple non-digestible oligosaccharides (NDOs), and short chain fatty acids (SCFA), as their metabolites produced by the gut microbiota, interact with enteropathogens and their toxins, which may result in the inhibition of the bacterial pathogenicity. NDOs characterized by diverse structural characteristics, block the pathogenicity of EPB either directly, by inhibiting bacterial adherence and growth, or biofilm formation or indirectly, by promoting gut microbiota. Apart from these abilities, NDOs and SCFA can interact with enterotoxins and reduce their cytotoxicity. These anti-virulent effects mostly rely on their ability to mimic the structure of toxin receptors and thus inhibiting toxin adherence to host cells. This review focuses on the strategies of EPB and related enterotoxins to impair host cell immunity, discusses the anti-pathogenic properties of NDOs and SCFA on EPB functions and provides insight into the potential use of NDOs and SCFA as effective agents to fight against enterotoxins.


2015 ◽  
Vol 6 (6) ◽  
pp. 783-790 ◽  
Author(s):  
H.K. Kim ◽  
N.B.M.M. Rutten ◽  
I. Besseling-van der Vaart ◽  
L.E.M. Niers ◽  
Y.H. Choi ◽  
...  

The composition of the gut microbiota plays a role in the development of allergies. Based on the immunomodulating capacities of bacteria, various studies have investigated the potential role for probiotics in the prevention of childhood eczema. In a previous study we have shown that significantly less children developed eczema after probiotic supplementation (Bifidobacterium bifidum W23, Bifidobacterium animalis subsp. lactis W52 and Lactococcus lactis W58, Ecologic®Panda) at three months of age as compared to controls. Here, metabolites in faecal samples of these 3-month old children were measured by 1H-nuclear magnetic resonance to investigate possible gut metabolic alterations. Lower amounts of short-chain fatty acids (SCFAs), succinate, phenylalanine and alanine were found in faecal samples of children later developing eczema, whereas the amounts of glucose, galactose, lactate and lactose were higher compared to the children not developing eczema. Although these differences were already present at the age of 3 months, eczema did not develop in the majority of children before the age of 1 year. Supplementation of multispecies probiotics seems to induce higher levels of lactate and SCFAs, and lower levels of lactose and succinate when compared with the placebo group. This might explain the temporary preventive effect of probiotics on the development of eczema. These results highlight the role bacterial metabolites may play in development of the immune system, even before clinical manifestations of allergic disease arise.


Sign in / Sign up

Export Citation Format

Share Document